Maintenance phase reduces to 2-3mg once weekly for 4-8 weeks to sustain healing progress
Every batch is third-party tested to 99% purity by HPLC, with a per-batch Certificate of Analysis (COA) available on request
Regulatory Status None of KLOW Blend's four components BPC-157, GHK-Cu, TB-500, or KPV is approved by the FDA as a drug for any indication
The table below does that, and the pattern it reveals is that the two peptides are studied for broadly similar goals but with different anchor points BPC-157 skewing toward gut and tendon rodent work, the thymosin beta-4 family toward dermal, corneal, and cardiac models
Given CJC-1295s status as a research chemical, any claims about this peptide's purported benefits have not been confirmed by human clinical trials and any statements online have not been evaluated by the FDA